Syndax Pharmaceuticals, Inc. Contract Liability (Deferred Revenue)
Syndax Pharmaceuticals, Inc. (SNDX) had Contract Liability (Deferred Revenue) of $1.52 million as of 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-03-01
- 2021-06-30: Contract with Customer, Liability, Current $1.52M.
- 2021-03-31: Contract with Customer, Liability, Current $1.52M.
- 2020-12-31: Contract with Customer, Liability, Current $1.52M.
- 2020-09-30: Contract with Customer, Liability, Current $1.52M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2021-06-30 | $1.52M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.52M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $1.52M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.52M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.52M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.52M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.52M 10-K · filed 2021-03-12 |
| 2019-09-30 | $1.52M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.52M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.52M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $1.52M 10-K · filed 2020-03-05 |
| 2018-09-30 | $1.52M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $1.52M 10-Q · filed 2018-08-08 |
| 2017-12-31 | $1.57M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |